Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...
Ironically, Ozempic and Wegovy, as with many of NovoNordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...
Results that may be inaccessible to you are currently showing.